Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by G1945Von Nov 03, 2015 6:02am
169 Views
Post# 24252767

RE:RE:RE:fun challenge to any true believer up to the task...

RE:RE:RE:fun challenge to any true believer up to the task...Hello, guys...This is how Sarah responded. You be the judge of it. 

I questioned the following on Oct 31:

Hello, again Sarah. Are you able to tell me;

a) if as yet RVX actually applied for ODD with the FDA and if so can you give me the date when it was done. It is my understanding that once 
an application is received by the FDA they have 90 days to respond.
b) and can you confirm that the BetOnMace trials actually begin when the first patient is treated ( or dosed ) and if so what is that date,
c) or does it actually begin when the patient selection preparation starts and if so has the patient selection started and if so when did it start. .

Your earliest response would be greatly appreciated.

Regards,

________________________________________________________________
Sarah's response on Nov 3: 

Yes we are actively working on Phase 3 approval from the FDA.  Their process is different than that used in Europe and other counties and as expected will take longer.  It is our policy not to publicize any discussions with the FDA while in progress and upon approval we will announce that particular milestone.  Our main focus remains the BETonMACE trial and we are deeply focused on executing it in an efficient and timely manner.

With regards to your question on BETonMACE; yes the trial has commenced as announced in our recent release. We have sites open with drug on-site which means enrollment and screening of patients has now commenced.

Best regards,

Sarah
Bullboard Posts